Abstract
Native α1-adrenoreceptors (ARs) appear to exist as three different subtypes encoded by three genes, α1A/1a, α1B/1b, and α1D/1d. Historically, the discovery of agents selective for each of the three α1-AR subtypes has been an active area of medicinal chemistry research because of the wide number of possible therapeutic applications. Initially introduced for the management of hypertension, α1-AR antagonists have, in fact, become increasingly common in the treatment of benign prostatic hyperplasia (BPH), and are effective therapeutic tools, when characterized by an appropriate uroselective profile. The majority of these derivatives display a competitive mechanism of action and belong to a variety of structural classes, but this review is focused on compounds belonging to the quinazoline, benzodioxane, arylpiperazine, and 1,4- dihydropyridine classes.
Keywords: Alpha-1 adrenoreceptors, alpha-1 adrenergic antagonists, quinazolines, benzodioxanes, arylpiperazines, 1,4- dihydropyridines
Current Topics in Medicinal Chemistry
Title: Recent Advances in α1-Adrenoreceptor Antagonists as Pharmacological Tools and Therapeutic Agents
Volume: 7 Issue: 2
Author(s): Michela Rosini, Maria L. Bolognesi, Dario Giardina, Anna Minarini, Vincenzo Tumiatti and Carlo Melchiorre
Affiliation:
Keywords: Alpha-1 adrenoreceptors, alpha-1 adrenergic antagonists, quinazolines, benzodioxanes, arylpiperazines, 1,4- dihydropyridines
Abstract: Native α1-adrenoreceptors (ARs) appear to exist as three different subtypes encoded by three genes, α1A/1a, α1B/1b, and α1D/1d. Historically, the discovery of agents selective for each of the three α1-AR subtypes has been an active area of medicinal chemistry research because of the wide number of possible therapeutic applications. Initially introduced for the management of hypertension, α1-AR antagonists have, in fact, become increasingly common in the treatment of benign prostatic hyperplasia (BPH), and are effective therapeutic tools, when characterized by an appropriate uroselective profile. The majority of these derivatives display a competitive mechanism of action and belong to a variety of structural classes, but this review is focused on compounds belonging to the quinazoline, benzodioxane, arylpiperazine, and 1,4- dihydropyridine classes.
Export Options
About this article
Cite this article as:
Rosini Michela, Bolognesi L. Maria, Giardina Dario, Minarini Anna, Tumiatti Vincenzo and Melchiorre Carlo, Recent Advances in α1-Adrenoreceptor Antagonists as Pharmacological Tools and Therapeutic Agents, Current Topics in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/156802607779318244
DOI https://dx.doi.org/10.2174/156802607779318244 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Erectile Dysfunction: An Under-Recognition of Hypertension
Current Pharmaceutical Design Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Aquaporins in Sensory and Pain Transmission
Current Neuropharmacology The Antihypertensive, Antimicrobial and Anticancer Peptides from <i>Arthrospira</i> with Therapeutic Potential: A Mini Review
Current Molecular Medicine Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Angiogenesis and Angiogenic Inhibitors in Non Small Cell Lung Cancer
Current Angiogenesis (Discontinued) Associations between Adiponectin Gene Variability, Proinflammatory and Angiogenetic Markers: Implications for Microvascular Disease Development in Type 2 Diabetes Mellitus?
Current Vascular Pharmacology Novel Orphan Nuclear Receptors-Coregulator Interactions Controlling Anti-Cancer Drug Metabolism
Current Drug Metabolism Maintenance of Gastrointestinal Glucose Homeostasis by the Gut-Brain Axis
Current Protein & Peptide Science Acute Cellular Oxygen Sensing in the Heart - A Role for Mitochondria?
Vascular Disease Prevention (Discontinued) Dietary Regulation of Glucose Metabolism in Metabolic Syndrome
Current Vascular Pharmacology Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy
Current Vascular Pharmacology Chronic Hyperuricemia, Uric Acid Deposit and Cardiovascular Risk
Current Pharmaceutical Design ENaC and Its Regulatory Proteins as Drug Targets for Blood Pressure Control
Current Drug Targets Cardiovascular Effects of Green Tea Catechins: Progress and Promise
Recent Patents on Cardiovascular Drug Discovery Reconsideration of Japanese Traditional Herbal Medicine: New Field of Research and Clinical Medicine
Mini-Reviews in Medicinal Chemistry Risk Factors for Cardiovascular Disease in Psoriasis: Relation to Inflammation Assessed by the Severity and Duration of Illness
Inflammation & Allergy - Drug Targets (Discontinued) subject Index To Volume 3
Current Drug Metabolism Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design Molecular Pathogenesis of Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms
Current Cancer Drug Targets